The Motley Fool

2 coronavirus vaccine success stocks I think could make UK investors rich

Of the 100+ coronavirus vaccines under investigation, some, like the one being developed by Oxford University and AstraZeneca, are showing real promise in clinical trials. In fact, Russia granted regulatory approval for a vaccine yesterday, although doubt has been expressed about the approval process and the efficacy of the vaccine.

Holding the stock of the company that develops a vaccine first might seem like the path to profit. However, some developers are private. Others are public companies but their stock is difficult to trade for UK investors. Those aren’t the only hurdles to successfully picking a successful coronavirus vaccine investment.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Coronavirus vaccine success

Developing a vaccine is one thing. Mass producing it is another. An investor might be able to back the right developer, only for them to struggle to produce enough doses. A company cannot truly win the vaccine race if multiple vaccines are approved. Another issue is that developers are rightly making promises to sell at least a chunk of vaccines at cost. 

To my mind, a better bet for profiting from a coronavirus vaccine is to back stocks that will do well regardless of who wins the vaccine race. Getting the world back to normal will happen faster with a vaccine than without one. Travel and leisure stocks were particularly badly hit by the coronavirus market crash. It stands to reason that they should benefit substantially from a return to normality, particularly if it does not take as long as had been feared.

Stocks that win regardless

I think InterContinental Hotels is a potential coronavirus vaccine success stock. It already has 95% of its sites open for business. Although the company reported a loss of $275m for the first half of 2020, this was not as bad as expected and included $255m in exceptional, and mainly non-cash, charges. A free cash outflow of $66m over the first six months of this year was better than expected.

Domestic travel is recovering faster than international. IHG’s core US business is benefitting from this, as are its other operations in countries across the world. IHG owns hotel brands that cater to every segment, from budget domestic right up to luxury international. Therefore it will cumulatively pick up revenues as different groups of travellers get back on the road, even without a vaccine. With a vaccine, IHG’s share price should get a real boost and shareholders would start receiving dividends sooner.

Another stock I think could boom with a coronavirus vaccine is National Express. After a strong bounce back from the depth of the coronavirus market crash, the share price of the US and European coach, school bus, and rail service operator has slumped again. A departing CEO selling his shares did not help. However, National Express earned record sales and profits in 2019, after a near decade-long turnaround.

National Express has slashed costs, raised equity, and has about £1.5bn in cash and credit. The company looks well-positioned for a staged recovery in travel. Again, this stock has the advantage of drawing a lot of business from domestic travel. A coronavirus vaccine will return the world closer to normal patterns of travel much quicker and should give the National Express share price a real boost.

Looking for another stock that is likely to soar with a coronavirus vaccine?

A Top Share with Enormous Growth Potential

Savvy investors like you won’t want to miss out on this timely opportunity…

Here’s your chance to discover exactly what has got our Motley Fool UK analyst all fired up about this ‘pure-play’ online business (yes, despite the pandemic!).

Not only does this company enjoy a dominant market-leading position…

But its capital-light, highly scalable business model has previously helped it deliver consistently high sales, astounding near-70% margins, and rising shareholder returns … in fact, in 2019 it returned a whopping £150m+ to shareholders in dividends and buybacks!

And here’s the really exciting part…

While COVID-19 may have thrown the company a curveball, management have acted swiftly to ensure this business is as well placed as it can be to ride out the current period of uncertainty… in fact, our analyst believes it should come roaring back to life, just as soon as normal economic activity resumes.

That’s why we think now could be the perfect time for you to start building your own stake in this exceptional business – especially given the shares look to be trading on a fairly undemanding valuation for the year to March 2021.

Click here to claim your copy of this special report now — and we’ll tell you the name of this Top Growth Share… free of charge!

James J. McCombie owns shares of National Express Group. The Motley Fool UK has recommended InterContinental Hotels Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.